---
document_datetime: 2023-09-21 20:27:40
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/myocet-liposomal-previously-myocet-epar-all-authorised-presentations_en.pdf
document_name: myocet-liposomal-previously-myocet-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7574544
conversion_datetime: 2025-12-28 04:52:47.896169
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                                                        | Route of Administration   | Immediate Packaging   | Content (concentration)                                       | Pack size                                             |
|------------------|-------------------|------------|----------------------------------------------------------------------------|---------------------------|-----------------------|---------------------------------------------------------------|-------------------------------------------------------|
| EU/1/00/141/001  | Myocet liposomal  | 50 mg      | Powder, dispersion and solvent for concentrate for dispersion for infusion | Intravenous use           | vial (glass)          | powder vial: 50 mg; liposomes vial: 1.9 ml; buffer vial: 3 ml | 2 sets of 3 vials (1 powder + 1 liposomes + 1 buffer) |
| EU/1/00/141/002  | Myocet liposomal  | 50 mg      | Powder, dispersion and solvent for concentrate for dispersion for infusion | Intravenous use           | vial (glass)          | powder vial: 50 mg; liposomes vial: 1.9 ml; buffer vial: 3 ml | 1 set of 3 vials (1 powder + 1 liposomes + 1 buffer)  |